PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of frontpharmacolLink to Publisher's site
 
Front Pharmacol. 2017; 8: 183.
Published online 2017 April 10. doi:  10.3389/fphar.2017.00183
PMCID: PMC5385379

Functional and Biochemical Endothelial Profiling In Vivo in a Murine Model of Endothelial Dysfunction; Comparison of Effects of 1-Methylnicotinamide and Angiotensin-converting Enzyme Inhibitor

Abstract

Although it is known that 1-methylnicotinamide (MNA) displays vasoprotective activity in mice, as yet the effect of MNA on endothelial function has not been demonstrated in vivo. Here, using magnetic resonance imaging (MRI) we profile the effects of MNA on endothelial phenotype in mice with atherosclerosis (ApoE/LDLR-/-) in vivo, in comparison to angiotensin (Ang) -converting enzyme (ACE) inhibitor (perindopril), with known vasoprotective activity. On a biochemical level, we analyzed whether MNA- or perindopril-induced improvement in endothelial function results in changes in ACE/Ang II-ACE2/Ang-(1–7) balance, and L-arginine/asymmetric dimethylarginine (ADMA) ratio. Endothelial function and permeability were evaluated in the brachiocephalic artery (BCA) in 4-month-old ApoE/LDLR-/- mice that were non-treated or treated for 1 month or 2 months with either MNA (100 mg/kg/day) or perindopril (10 mg/kg/day). The 3D IntraGate®FLASH sequence was used for evaluation of BCA volume changes following acetylcholine (Ach) administration, and for relaxation time (T1) mapping around BCA to assess endothelial permeability using an intravascular contrast agent. Activity of ACE/Ang II and ACE2/Ang-(1–7) pathways as well as metabolites of L-arginine/ADMA pathway were measured using liquid chromatography/mass spectrometry-based methods. In non-treated 6-month-old ApoE/LDLR-/- mice, Ach induced a vasoconstriction in BCA that amounted to –7.2%. 2-month treatment with either MNA or perindopril resulted in the reversal of impaired Ach-induced response to vasodilatation (4.5 and 5.5%, respectively) and a decrease in endothelial permeability (by about 60% for MNA-, as well as perindopril-treated mice). Improvement of endothelial function by MNA and perindopril was in both cases associated with the activation of ACE2/Ang-(1–7) and the inhibition of ACE/Ang II axes as evidenced by an approximately twofold increase in Ang-(1–9) and Ang-(1–7) and a proportional decrease in Ang II and its active metabolites. Finally, MNA and perindopril treatment resulted in an increase in L-arginine/ADMA ratio by 107% (MNA) and 140% (perindopril), as compared to non-treated mice. Functional and biochemical endothelial profiling in ApoE/LDLR-/- mice in vivo revealed that 2-month treatment with MNA (100 mg/kg/day) displayed a similar profile of vasoprotective effect as 2-month treatment with perindopril (10 mg/kg/day): i.e., the improvement in endothelial function that was associated with the beneficial changes in ACE/Ang II-ACE2/Ang (1–7) balance and in L-arginine/ADMA ratio in plasma.

Keywords: endothelial function, atherosclerosis, MRI, 1-methylnicotinamide, perindopril, plasma angiotensin profile, L-Arg/ADMA ratio

Introduction

1-Methylnicotinamide (MNA), the major metabolite of NA synthesized in the liver in the reaction involving NNMT, when given exogenously has distinct therapeutic activity, despite the fact, that it has long been considered inactive (Aksoy et al., 1994). Indeed, topical MNA alleviates the inflammatory responses in skin diseases such as acne, contact dermatitis or rosacea (Gebicki et al., 2003; Wozniacka et al., 2005). In turn, systemic administration of MNA exerts anti-thrombotic (Chlopicki et al., 2007), anti-inflammatory (Bryniarski et al., 2008), and gastroprotective (Brzozowski et al., 2008) properties mediated by the activation of COX-2 and PGI2 pathways. Furthermore, MNA can improve endurance exercise capacity in mice with diabetes, and may decrease the cardiovascular risk of exercise (Przyborowski et al., 2015). MNA was demonstrated to have hepatoprotective activity against concanavalin A-induced liver injury through the downregulation of IL-4 and TNF-α signaling (Sternak et al., 2010; Jakubowski et al., 2016), and to inhibit metastasis formation in a murine model of metastatic mammary gland cancer (4T1) in BALB/c mice (Blazejczyk et al., 2016). Interestingly, 1-MNA has also been shown to restore endothelial function in diabetic hypertriglycemic rats (Bartuś et al., 2008) analyzed ex vivo in isolated aorta, suggesting that the improvement in endothelial function may represent an important target of MNA activity and may explain therapeutic efficacy of MNA in various diseases including diabetes (Watała et al., 2009) and atherosclerosis (Mateuszuk et al., 2016). Indeed, in our recent study anti-atherosclerotic effects of MNA in ApoE/LDLR-/- mice, including the inhibition of inflammatory burden in plaques, diminished systemic inflammation, diminished platelet activation that were associated with an improvement in PGI2 and NO-dependent endothelial function. These results support the notion that pronounced effects of MNA on endothelial function could contribute to therapeutic efficacy of MNA (Mateuszuk et al., 2016). However, in none of the previous experimental studies of MNA was endothelial function assessed in vivo, but only in ex vivo vascular preparation (Bartuś et al., 2008; Mateuszuk et al., 2016).

Endothelial dysfunction, being a consequence of vascular homeostatic imbalance is a hallmark of various cardiovascular diseases including atherosclerosis (Anderson et al., 1995), hypertension (Dharmashankar and Widlansky, 2010), heart failure (Marti et al., 2012), as well as non-cardiovascular diseases such as cancer (Franses et al., 2013). Vascular dysfunction is associated with activation of pro-inflammatory signaling molecules including adhesion molecules, chemokines and cytokines (Karbach et al., 2014; Steven et al., 2015). There is also evidence that ROS play an important role in vascular inflammation (Zhou et al., 2011) and tissue damage (Mittal et al., 2014). There are number of enzymatic sources of endothelial ROS, including eNOS uncoupling, converting beneficial NO synthase into a detrimental superoxide-producing enzyme (Karbach et al., 2014; Schulz et al., 2014).

Currently, many biochemical assays and functional tests are used for the evaluation of impaired NO-dependent function, oxidant stress and pro-inflammatory phenotype of endothelial dysfunction in humans. Prognostic value of biochemical measurements of endothelial biomarkers is still not widely accepted (Walczak et al., 2015). However, endothelial function measurements based on the assessment of impairment of NO-dependent vasodilatation in the coronary and peripheral circulation have prognostic importance in predicting adverse cardiovascular events (Schächinger et al., 2000; Halcox et al., 2002). In particular, a non-invasive endothelial function assessment, based on monitoring the brachial artery diameter with a two-dimensional ultrasound, before and after artery occlusion is considered a gold-standard method (Frolow et al., 2015). MRI has also successfully been used for non-invasive measurement of FMD in humans (Lee et al., 2007; Canton et al., 2012; Redheuil, 2014; Teixido-Tura et al., 2014), but studies of endothelial functional phenotype in mice in vivo are associated with greater technical challenges (Botnar and Makowski, 2012). Given high spatio-temporal resolution of MRI, it seems to be the method of choice to assess endothelium-dependent response in mice. Indeed, MRI-based tests could provide an excellent tool to gain better insight into endothelium-dependent mechanisms in experimental studies in mice (Gotschy et al., 2013; Herold et al., 2009). Phinikaridou et al. (2012) were the first to describe an MRI-based method for the noninvasive assessment of endothelial-dependent vasodilatation and permeability in vivo in mice, with the use of an albumin-binding magnetic resonance CA. In our recent studies, we developed a 3D MRI-based assessment of endothelium-dependent vasodilatation induced by acetylcholine (Ach) and endothelial permeability fully based on the use of retrospectively self-gated 3D gradient-echo sequence (Bar et al., 2016). The developed approach has been validated in two distinct murine models of endothelial dysfunction, including atherosclerotic (ApoE/LDLR-/- mice) and HFD-fed mice, showing that our approach allows for a reliable detection of the impairment of NO-dependent vasodilatation and changes in endothelial permeability.

Genetically modified mice without apolipoprotein E and receptor for low density lipoprotein (mouse apolipoprotein E-deficient and Low-Density Lipoprotein Receptor-Deficient Double Knockout, ApoE/LDLR-/-), constitute reliable mouse model of endothelial dysfunction linked to atherosclerosis. In this strain of mice, spontaneously atherosclerosis develops without administration of atherogenic diet (Kostogrys et al., 2012), and endothelial dysfunction precedes the atherosclerotic plaque development (Csányi et al., 2012), similarly as it occurs in humans. In turn, the early development of endothelial dysfunction in single ApoE-/- mice was not univocally accepted (Crauwels et al., 2003; Villeneuve et al., 2003).

Given that the assessment of the endothelial phenotype in vivo in a reliable mouse model of endothelial dysfunction is essential for the preclinical profiling of vasoprotective compounds, the aim of the present study was to take advantage of the 3D MRI-based method to profile effects of MNA on functional phenotype of endothelium in ApoE/LDLR-/- mice in vivo, in comparison to standard vasoprotective treatment such as ACE-I (perindopril), that is known to display significant vasoprotective effect in various experimental models including atherosclerosis (Chłopicki and Gryglewski, 2005). We also analyzed whether MNA- or perindopril-induced improvement in endothelial function is associated with biochemical changes in plasma in ACE/Ang-II-ACE2/Ang-(1–7) balance and L-Arg/ADMA ratio.

Materials and Methods

Animals

In this study, 4-month-old ApoE/LDLR-/- mice (body weight of 20–30 g), bred in the Department of Human Nutrition, University of Agriculture (Krakow, Poland), were transported to the animal house at Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University (Krakow, Poland) and were treated for 1 or 2 months with MNA (syntethized by dr Jan Adamus, Technical University in Lodz, Poland: 100 mg/kg/day in diet) or perindopril (a gift from Servier, Warszawa Poland: 10 mg/kg/day in drinking water). Doses of compounds used in this study were based on our previous published (Chlopicki et al., 2007; Mateuszuk et al., 2016) and unpublished studies, for MNA and perindopril, respectively. Two groups of 4-month-old ApoE/LDLR-/- mice were left untreated (as control groups) for 1 and 2 months, respectively. The sizes and names of the experimental groups are reported in the legends of the corresponding graphs. All mice were bred in standard conditions (LD: 12/12, humidity: 60%, temperature: 23°C), and housed in pathogen-free conditions. Prior to the MRI experiment, the animals were transported to the animal house at the Institute of Nuclear Physics (Krakow, Poland) to assess endothelial phenotype in vivo. After in vivo measurements, mice were sacrificed in order to collect blood. The experimental design is illustrated in Supplementary Figure S1. All experiments were approved by the Ethics Local Committee of Jagiellonian University (Krakow, Poland) and were compliant with the Guide for the Care and Use of Laboratory Animals of the National Academy of Sciences (NIH publication No. 85–23, revised 1996).

In Vivo Assessment of NO-dependent Endothelial Response to Ach and Endothelial Permeability by MRI

MRI experiments were performed using a 9.4T scanner (BioSpec 94/20 USR, Bruker, BioSpin GmbH, Germany), as described previously (Bar et al., 2016). Mice were anaesthetized using isoflurane (Aerrane, Baxter Sp. z o. o., Warszawa, Poland, 1.7 vol. %) in an oxygen and air (1:2) mixture. Body temperature was maintained at 37°C using circulating warm water. ECG, respiration and body temperature were monitored using a Model 1025 Monitoring and Gating System (SA Inc., Stony Brook, NY, USA). Mice were imaged in the supine position to test the vasomotor response of the vessel. 3D images of the aortic arch prior to and 25 min after intraperitoneal Ach administration (Sigma–Aldrich, Poznan Poland: 50 μl, 16.6 mg/kg) were acquired using the cine IntraGateTM FLASH 3D sequence and reconstructed with the IntraGate 1.2.b.2 macro (Bruker, BioSpin GmbH, Germany). T1 maps were measured before and 30 min after intravenous administration of albumin-binding gadolinium CA (Galbumin, BioPal, Worcester, MA, USA – 25 mg/ml, 4.5 ml/kg) using the VFA technique (Cheng and Wright, 2006; Wang et al., 2006), by sampling the signal, using varying values of flip angles and then fitting the result to an expected T1-dependent signal model. Imaging parameters for endothelial function assessment included the following: repetition time (TR) – 6.4 ms, echo time (TE) – 1.4 ms, field of view (FOV) – 30 mm × 30 mm × 5 mm, matrix size – 256 × 256 × 30, flip angle (FA) – 30°, and number of accumulations (NA) – 15, reconstructed to seven cardiac frames. Total scan time was 10 min. Imaging parameters for endothelial permeability assessment included the following: TR – 10 ms, TE – 1.1 ms, FOV – 30 mm × 30 mm × 4 mm, matrix size – 192 × 160 × 8, number of repetitions – 12, and reconstructed to one cardiac frame. Eight FA were used: 2°, 4°, 6°, 8°, 14°, 20°, 30°, 50°. FA values were set by changing the length of a radiofrequency pulse, with constant amplifier power. Total scan time for all angles was 16 min. The experimental design is illustrated in Supplementary Figure S1.

MRI Data Analysis

Time-resolved 3D images of the aortic arch (Figure Figure1A1A) were analyzed to endothelial function assessment in BCA, using ImageJ software 1.46r (NIH Bethesda, MD, USA) and scripts written in Matlab (MathWorks, Natick, MA, USA). Images were reconstructed to seven cardiac frames and imported into ImageJ as a hyperstack (Figure Figure1B1B matrix: 256 × 256, slices: 30, frames: 7). Further analysis was performed in diastole of BCA, using small hyperstack (Figure Figure1B1B marked in red color matrix: 256 × 256, slices: 5, frames: 1) starting at the base of the vessel and ending just before the branch. Cross-sectional areas of BCA at each slices were obtained using thresholding segmentation and exported to Matlab, where BCA volumes were reconstructed and calculated. Detailed analysis was described in Supplementary Material of our previous work (Bar et al., 2016). In order to endothelial permeability assessment, obtained images were used to calculate the T1 around the BCA lumen before and after CA administration. The signal model was fitted pixel by pixel using Matlab software developed in house. Two T1 maps (before and after CA administration) were compared, using scripts written in Matlab, and pixels for which T1 had changed significantly (by more than 50%) after CA administration were marked in red (Figure Figure1C1C). The threshold value (50%) was determined experimentally. All red pixels were counted by program as number of pixels, for which T1 had changed more than 50% after CA administration (Npx50).

FIGURE 1
Methodology to assess endothelium-dependent response and changes in endothelial permeability in brachiocephalic artery (BCA) in vivo by MRI. (A) Coronal view of the heart. Image showing position of the imaging layer (IL) used for 3D imaging of the aortic ...

Measurement of Ang Profile in Plasma

The blood was drawn from the heart, collected in tubes containing heparin (20 units/ml) and immediately mixed with protease inhibitor cocktail (Sigma–Aldrich, Poznan, Poland) in a ratio of 19:1 (v/v), and centrifuged at 1,000 × g for 10 min to isolate plasma. Afterward, the resulting plasma was transferred into Protein LoBind tubes (Eppendorf, Hamburg, Germany), split into aliquots and stored frozen at -80°C until analysis.

Protein precipitation with ACN was used as the sample pre-treatment method to remove high molecular plasma compounds. CS, QC samples, and RS were created by spiking 25 μl (pooled blank – CS, QC) plasma with 20 μl appropriate working standard solution or water (RS) and 5 μl IS – [Asn1, Val5]-Ang II (2,500 pg/ml). Calibration curve standards were made at: 10; 50; 100; 250; 300; 400; 500 pg/ml (IS – 250 pg/ml) concentrations, respectively. CS at seven different concentration levels or adequate QC and RS were deproteinized with ACN (in 4:1 (v/v) proportion to the samples used) and assayed.

The LC-MS/MS analyses of plasma samples were performed on an UltiMate 3000 Rapid Separation nano-LC system (Dionex, Thermo Scientific, San Jose, CA, USA) interfaced via a ChipMateTM nanoelectrospray ion source (Advion, USA) to a TSQ Vantage triple quadrupole mass spectrometer (Thermo Scientific). The samples were injected in 5 μl aliquots onto a trapping column for desalting and concentrating of the analytes which in the next step was switched in-line with the separation C18 column to elute the peptides at a flow rate of 300 nl/min with an increasing percentage of the organic solvent. Separation was accomplished using a gradient of phase A (acetic acid (1%, v/v) in H2O) and phase B (acetic acid (1%, v/v) in ACN) as follows: 2% B for 5 min, 2–98% B for 15 min, and 98% B for 5 min. The mass spectrometer was operated in the positive ion mode and the detection of Ang peptides in MRM mode was performed. The two most sensitive/specific ion transitions were measured for each of the 9 Ang peptides determined [Ang I, II, III, IV, (1–7), (1–9), Ang A, alamandine and Ang-(1–12)]. Analytical method details as well as the MS/MS transitions monitored in the protocol are described elsewhere (Olkowicz et al., 2016). Instrument control, data collection, and analysis were achieved with the Thermo Xcalibur (version 2.1) software.

Measurement of Flux Through L-Arg Metabolic Pathways

Plasma amino acid concentrations were determined using a Surveyor HPLC system (Thermo Scientific) coupled to a TSQ Vantage Triple-Stage Quadrupole mass spectrometer, as described recently (Smolenska et al., 2016). Briefly, an aliquot of plasma (50 μl) was deproteinized with 100 μl of ACN maintained in ice. The tubes were then centrifuged at 4°C, 16,000 × g for 10 min and the resultant supernatant was collected and subjected to freeze-drying. The residue was next reconstituted with 50 μl of H2O acidified with 0.1% (v/v) FA and analyzed using an LC/MS system as detailed below.

Chromatographic separation was achieved using a Synergi Hydro-RP column (50 mm × 2.0 mm i.d., 2.5 μm) fitted with a security guard (Phenomenex, Torrance, CA, USA). The mobile phase consisted of a mixture of phase A (5 mM NFPA in water) and phase B (0.1% (v/v) FA in ACN), that was delivered at 0.2 ml/min in a gradient from 0 to 45% B in 5.5 min. The effluent of the HPLC column was directed to the electrospray Ion-Max source of the mass spectrometer that was operated in MRM mode. The settings of the ion source were as follows: needle voltage, +4.5 kV; sheath gas pressure, 30 (arbitrary units); auxiliary gas pressure, 3 (arbitrary units), and capillary temperature, 250°C. Additionally, to overcome the possible reduction of the signal intensity due to perfluorinated carboxylic acid use, we added 0.05% (v/v) FA in methanol at 0.2 ml/min as the post-column sheet flow. The LC/MS system, data acquisition and processing were managed by the Xcalibur software (v. 2.1, Thermo Scientific).

Statistical Analysis

All of the data obtained are presented as mean and standard error of the mean (SEM) or in case of the lack of normal distribution as median and range. Statistical tests were done using STATISTICA 10 (Stat Soft Inc., USA) or GraphPad Prism 5 (GraphPad Software, Inc., CA, USA) software. Non-parametric test (Kruskal–Wallis test) or parametric test (one-way ANOVA followed by Tukey’s post hoc test) were performed. Pearson or Spearman correlation coefficient tests were used to assess dependence between two parameters. Statistical significance was defined as p < 0.05.

Results

Effects of MNA and Perindopril Treatment on Endothelium-dependent Vasomotor Response and Changes in Endothelial Permeability in ApoE/LDLR-/- Mice In Vivo

In non-treated ApoE/LDLR-/- mice, injection of Ach (16.6 mg/kg given i.p. in the volume of 50 μl) resulted in vasoconstriction of BCA. Endothelium-dependent response of BCA after Ach administration amounted to –2.39 and –7.18% for 5-month-old and 6-month-old ApoE/LDLR-/- mice, respectively. In mice treated with MNA or perindopril for a 1-month period (Figure Figure2A2A), endothelium-dependent response improved and an increase in volume of BCA after Ach injection was observed (by about 9 and 3%, respectively). Treatment of ApoE/LDLR-/- mice for 2 months with MNA or perindopril further improved endothelium-dependent vasodilation as well as decreased endothelial permeability (Figure Figure2B2B). The number of pixels around BCA, for which T1 had changed more than 50% after CA administration (Npx50) was smaller in mice treated with MNA and perindopril than in non-treated ApoE/LDLR-/- mice (Npx50 was 6.0, 6.0, and 15.0, respectively, Figure Figure2B2B). Interestingly, there was a significant correlation between endothelium-dependent response of BCA and Npx50 (Table Table11).

FIGURE 2
Effects of MNA and ACE-I (perindopril) treatment on endothelial function and permeability in vivo in ApoE/LDLR-/- mice. Changes in end-diastolic volume of BCA 25 min after Ach administration (A) and number of pixels around BCA, for which T1 had changed ...
Table 1
Correlation between parameters of functional and biochemical endothelial profiling in vivo.

Effects of MNA and Perindopril Treatment on Plasma Ang Profile

The pattern of changes in plasma Ang profile of ApoE/LDLR-/- mice treated for one month with MNA was largely convergent with those observed in plasma of mice treated with perindopril (as compared to non-treated animals), and involved an increase in concentration of Ang-(1–7) [by 36% (MNA), 95% (perindopril)], alamandine [by 18% (MNA), 47% (perindopril)], and Ang-(1–9) [by 72% (MNA), 173% (perindopril)] in comparison to untreated ApoE/LDLR-/- mice (Figure Figure3A3A). At the same time, the level of Ang II and other pathological effectors of the RAS (Ang III, IV, A) significantly decreased. The most pronounced differences were observed in the content of Ang II and its N-terminally truncated metabolite – Ang III, the level of which nearly halved as compared to the control, untreated animals [from 119.8 ± 11.3 to 85.5 ± 5.4 (MNA) and to 50.2 ± 4.1 (perindopril) fmol/ml for Ang II, from 206.2 ± 15.5 to 130.4 ± 10.0 (MNA), and to 96.2 ± 8.7 (perindopril) fmol/ml for Ang III, respectively]. These changes were accompanied by a slight increase in the content of precursor peptides: Ang I [by 21% (MNA) and 34% (perindopril) versus non-treated mice] and Ang-(1–12) [by 18% (MNA) and 43% (perindopril) as compared to control animals]. Activation of counter-regulatory ACE2/Ang-(1–7)/Ang-(1–9) axis with concomitant inhibition of ACE/Ang II pathway was further highlighted after two months of treatment with MNA or perindopril whereby the beneficial effect of MNA treatment was even more similar to that exerted by perindopril (Figure Figure3B3B). Interestingly, there was a significant correlation between Ang-(1–7)/Ang II ratio and endothelium-dependent response of BCA or Npx50 (Table Table11).

FIGURE 3
Effects of MNA and ACE-I (perindopril) treatment on plasma Ang profile in ApoE/LDLR-/- mice. Plasma Ang profile in non-treated ApoE/LDLR-/- mice (columns with diagonal lines) and in ApoE/LDLR-/- mice treated with MNA (black columns) or perindopril (columns ...

Effects of MNA and Perindopril Treatment on L-Arg/ADMA Ratio in Plasma

Endothelial function is critically dependent on eNOS activity and consequently adequate NO bioavailability. Treatment with both MNA and perindopril was associated with alterations in amino acid metabolism engaged in NO generation. Plasma concentration of L-Arg that serves as a substrate for the formation of NO by the NOS enzymes was elevated after just one month of treatment with both MNA (by 25%) and perindopril (21%) as compared to untreated ApoE/LDLR-/- mice (Figure Figure4A4A). Furthermore, the plasma concentration of precursors of L-Arg (L-citrulline and L-ornithine) was increased in parallel. These changes were accompanied by a decrease in methylated Arg concentration. After 1 month of treatment, ADMA that is perceived as an endogenous inhibitor of all NOS enzymes (including eNOS) was diminished by 10% (MNA) and 17% (perindopril), respectively (in comparison to non-treated animals). Two months of pharmacotherapy led to a further decline in the plasma concentration of ADMA [by 15% (MNA) and by 20% (perindopril), respectively] (Figure Figure4B4B). Plasma concentration of SDMA, recognized as a competitive inhibitor of cellular L-Arg transport was also decreased after 1 and 2 months of treatment with MNA or perindopril, but these changes did not reach statistical significance. Moreover, reduced concentration of methylated Arg was associated with an increase in the content of Met and concomitant decrease in the level of Hcy. Consequently, plasma L-Arg/ADMA ratio reflecting NO bioavailability was clearly elevated after 1 month of treatment with both MNA (by 34%) and perindopril (by 46%), and this effect was further maintained after 2 months of treatment. Interestingly, there was a significant correlation between L-arginine/ADMA ratio and endothelium-dependent response of BCA or Npx50 (Table Table11).

FIGURE 4
Effects of MNA and ACE-I (perindopril) treatment on L-arginine/ADMA ratio in plasma in ApoE/LDLR-/- mice. Plasma concentration of L-Arg, its precursors (L-Cit, L-Orn), ADMA, SDMA, Met, Hcy as well as L-Arg/ADMA ratio in non-treated ApoE/LDLR-/- mice (columns ...

Discussion

In the present work, we profiled endothelial activity of MNA in comparison with perindopril (ACE-I) using functional 3D MRI–based in vivo assays of endothelial function in parallel to biochemical measurements of ACE/Ang II-ACE2/Ang-(1–7) balance, and L-Arg/ADMA ratio in plasma. We demonstrated in vivo in ApoE/LDLR-/- mice, that treatment with MNA or perindopril resulted in the reversal of Ach-induced vasoconstriction response to vasodilatation and a concomitant decrease in endothelial permeability. Functional improvement of endothelial function by MNA or perindopril treatment was in both cases associated with the inhibition of ACE/Ang II axis and parallel activation of ACE2/Ang-(1–7) axis as evidenced by a fall in plasma concentration of Ang II, and its N-terminally truncated metabolites (Ang III and IV) and an increase in Ang-(1–9) and Ang-(1–7) plasma concentration. Furthermore, MNA and perindopril treatment resulted in an increase in L-arginine/ADMA ratio compatible with improvement of NO-dependent endothelial function. Altogether, our results suggest that MNA displayed a similar pattern of vasoprotective activity as perindopril, a representative of ACE-Is, and both compounds affected ACE/Ang II-ACE2/Ang-(1–7) balance and L-Arg/ADMA ratio that could contribute to their vasoprotective effects. Given that correction of endothelial function by ACE-Is contributes significantly to their clinical benefits and their anti-inflammatory, anti-thrombotic, anti-diabetic, and vasoprotective actions reported in numerous experimental and clinical papers (Chłopicki and Gryglewski, 2005), the findings of endothelial profile of MNA being similar to perindopril in in vivo settings bring important novel perspectives to understanding the therapeutic efficacy of MNA reported previously (Gebicki et al., 2003; Wozniacka et al., 2005; Chlopicki et al., 2007; Bartuś et al., 2008; Bryniarski et al., 2008; Brzozowski et al., 2008; Watała et al., 2009; Sternak et al., 2010; Przyborowski et al., 2015; Blazejczyk et al., 2016; Jakubowski et al., 2016; Mateuszuk et al., 2016).

In this study, endothelial function in vivo assessment was performed in BCA, in response to intraperitoneal administration of Ach. Importantly, endothelium-dependent response was independent of the effect of Ach on the heart and respiration (Bar et al., 2016). Undoubtedly, the important advantage of the use of MRI-based method is a retrospective reconstruction of images from 3D data sets, which allows for assessment of response of the entire vessel instead of only one fragment of the vessel. Moreover, the method provides the possibility of accurate positioning after experiment, whereby the effects of endothelial pharmacotherapy can be assessed, even in small vessels such as BCA, across various cross-sections to be located in planes perpendicular to the vessel. The 3D gradient echo sequence allows the avoidance of precise slice positioning during measurements, as arbitrary re-slicing during post-processing is possible with shorter time of the measurements. Importantly, in the present work an MRI-based method to assess endothelial permeability changes was also employed. We assessed the number of pixels (around the BCA) for which T1 had changed more than 50% (Npx50), as described previously (Bar et al., 2016). Npx50 parameter allows avoiding precise determination of ROI, what is difficult to establish objectively. Finding the pixels for which T1 had changed more than 50%, allows for operator-independent assessment of the ROI around the vessel. Analysis of changes in endothelial permeability represents an important feature of endothelial dysfunction, and its measurements seem a valuable test to analyze endothelial state in vivo. When endothelial permeability increases, leaky intercellular junctions of endothelium allow access to low-density lipoprotein particles and transmigration of leukocytes that are critical in atherosclerotic plaque formation (Kao et al., 1995). Moreover, albumin-binding CA can also accumulate in vessel walls (Lobbes et al., 2009; Pedersen et al., 2011), and this results in shortening of the T1 in the vessel wall enabling MRI-based detection, and Npx50-based operator-independent assessment of endothelial permeability (Bar et al., 2016). Importantly, in the present work, analysis of endothelial-dependent response by Ach as well as endothelial permeability based on Npx50 displayed significant negative correlation and gave concordant results showing improvement after MNA and perindopril treatment. Experiments carried out in this paper support the notion that MRI-based technique based on the retrospectively self-gated 3D IntraGate® FLASH sequence (Bar et al., 2016) is useful for monitoring the efficacy of endothelium-targeted therapy in murine models of diseases in vivo and seems far superior to ultrasound (Cavalcante et al., 2011).

In non-treated ApoE/LDLR-/- mice, injection of Ach resulted in paradoxical vasoconstriction, what was most likely due to a smooth muscle muscarinic receptor-dependent response, as also shown for human arteries with endothelial dysfunction (Ludmer et al., 1986). Treatment with MNA or perindopril resulted in shifting the Ach response to a vasodilatation, which indicates improvement in endothelial function. Comparing results of changes in BCA volume after acetylcholine administration in 5-month-old C57BL/6J mice (9.3%) published in our previous paper (Bar et al., 2016), to ApoE/LDLR-/- mice after two-month treatment with MNA (4.5%) or perindopril (5.5%) performed in present study, it seems that either treatment considerably improved the impaired endothelium-dependent response. It is worth noting that, after one-month treatment effects of perindopril seemed to be more pronounced as compared with the effect of MNA, but this difference disappeared after two months of treatment. Improvement in endothelial permeability was also similar in magnitude for MNA and perindopril after two months of treatment, supporting the similar pattern of endothelial response to MNA given in a dose of 100 mg/kg b.w./day in comparison to perindopril given in a dose of 10 mg/kg b.w./day.

An important finding of the present study was the demonstration that improvement of endothelial function by MNA and perindopril treatment, evidenced by MRI-based assays, was in both cases associated with the inhibition of the classical RAS pathway – ACE/Ang II/AT1R and concomitant activation of counter-regulatory RAS pathway – ACE2/Ang-(1–7)/Mas. Numerous previous studies clearly indicate that the RAS plays a critical role in the initiation and progression of atherosclerosis with endothelial dysfunction as its early event, and that the balance between two major axes of RAS, i.e., ACE/Ang II and ACE2/Ang-(1–7), is a key determinant of RAS beneficial vs. detrimental effects (Wang et al., 2013; Olkowicz et al., 2015; Cahill and Redmond, 2016). Ang II is considered as a pro-atherosclerotic mediator which causes vasoconstriction, regulates adhesion molecule (ICAM-1, VCAM-1, P-selectin) expression as well as chemokine, cytokine, and growth factor secretion within the arterial wall (Jiang et al., 2014). On the other hand, ACE2, through its product Ang-(1–7) displays anti-atherosclerotic properties in vivo, including decreasing inflammation and oxidative stress, and inhibiting inflammatory cell infiltration. The protective effect of ACE2, mainly distributed in ECs, VSMCs, and macrophages, was repeatedly demonstrated. Overexpression of ACE2 by gene transfer attenuated the progression of atherosclerotic lesions when the ACE2 gene was transferred 4 weeks after injury in a rabbit model of atherosclerosis (Dong et al., 2008). Similarly, overexpression of ACE2 in ApoE-deficient mice decreased atherosclerotic lesion size within the aortic sinus as compared to control mice (Lovren et al., 2008). In contrast, ACE2-deficiency in LDLR-/- as well as ApoE-/- genetic background mice increased the development of atherosclerosis (Thomas et al., 2010; Thatcher et al., 2011).

Our results not only confirmed that perindopril-induced a vasoprotective shift in the balance of ACE/Ang II and ACE2/Ang-(1–7), but also underscored that the profile of MNA is similar to that exerted by perindopril. Zhuo et al. (2002) have recently demonstrated that the clinical benefits of chronic ACE inhibition with perindopril, in addition to the blockade of systemic and tissue Ang II formation, may be in part due to elevated bradykinin levels, which in turn lead to increased NO bioavailability. Bradykinin was shown to be the major mediator of ACE-I-induced anti-thrombotic effects (Gryglewski et al., 2003, 2005; Chłopicki and Gryglewski, 2005). We did not study here the relative contribution of Ang II–dependent and bradykinin–dependent pathway to perindopril-induced improvement in NO-dependent function, but obviously it cannot be excluded that both pathways may be involved in perindopril-induced improvement in endothelial function. Whether the same mechanisms contribute to MNA- induced effects remains to be established. Interestingly, in our previous studies describing anti-atherosclerotic effects of MNA, an improvement in NO–dependent endothelial function, observed in ex vivo vascular preparations was also associated with activation of PGI2–dependent function (Mateuszuk et al., 2016). Altogether, the results presented here suggest that MNA- induced shift in the balance of ACE/Ang II and ACE2/Ang-(1–7) toward the vasoprotective axis may contribute to the improvement of endothelial function by MNA or alternatively may constitute an important pathophysiological sign of improved endothelial function.

We also demonstrated that MNA and perindopril treatment resulted in an increase in L-arginine/ADMA ratio that was compatible with improvement of NO-dependent endothelial function. Given the fact, that circulating level of ADMA adds independent prognostic information with regard to cardiovascular risk beyond that obtained from classical risk factors and novel biomarkers (Schnabel et al., 2005) this finding is of importance. In fact, plasma concentrations of ADMA have been found to be significantly elevated in patients with arteriosclerosis, as well as in those with coronary risk factors, such as hypertension or hypercholesterolemia, and marked increase in ADMA level has been associated with impaired endothelium-dependent NO-mediated vasodilatation (Böger et al., 1997, 1998; Surdacki et al., 1999; Böger, 2003) that may be linked to decreased activity of y+LAT as the major export pathway for the ADMA (Closs et al., 2012). Interestingly, Suda et al. (2004) have recently reported that the long-term vascular effects of ADMA are not solely mediated by inhibition of endothelial NO synthesis but also can lead to direct upregulation of ACE expression and increased oxidative stress through AT1 receptor activation. Moreover, they have proposed that inhibition of NO synthesis appears primarily as a result of short-term action of ADMA; as long as metabolites of ADMA accumulate at higher concentrations in blood vessels, eNOS-independent mechanisms predominate. Involvement of multiple mechanisms in vascular effects of ADMA, other than simple inhibition of endothelial NO synthesis, including also upregulation of ACE, remains to be clarified. In a recent work of Jiang et al. (2016) it was reported that MNA attenuated atherogenesis via modulation of the ADMA-DDAH pathway in ApoE-deficient mice. The beneficial effect of MNA treatment was associated with the upregulation of the DDAH2 enzyme activity in endothelium via the mitigation of hypermethylation in the promoter region of the enzyme. These results seem consistent with our observations showing the reduction in plasma ADMA concentration as well as Hcy concentration that was linked to an improved endothelium-dependent vascular relaxation after MNA. Interestingly, Huang et al. (2015) showed that Hcy synthesized in endothelium (after Met administration) affected activity of ACE by direct homocysteinylation of its amino- and/or sulfhydryl- moieties. This modification enhanced ACE reactivity toward Ang II and consequently led to NADPH oxidase-superoxide-dependent endothelial dysfunction. In that context, treatment with MNA and perindopril attenuates various apparently interlinked biochemical changes closely associated with functional phenotype of endothelial dysfunction such as excessive activation of ACE, elevation of ADMA and Hcy that can all contribute to vasoprotective action of these compounds resulting in the improvement of endothelial function reported here in vivo using functional and biochemical measurements.

Indeed, there was a significant positive correlation between endothelium-dependent response of BCA after acetylcholine administration and the two major biochemical parameters measured here [L-arginine/ADMA ratio and Ang-(1–7)/Ang II]. In turn, since the improvement of endothelial dysfunction was associated with a decrease in endothelial permeability, correlation between Npx50 and biochemical parameters [L-arginine/ADMA ratio and Ang-(1–7)/Ang II] had negative character. Similar correlations between ADMA concentration and Ach- or flow-induced vasodilatation have also been demonstrated previously in monkeys with hypercholesterolemia, using endothelium-dependent vascular function ex vivo assessment (Böger et al., 2000) as well as in humans with hypercholesterolemia using ultrasonography (Böger et al., 1998).

Effects of treatment with MNA and perindopril on atherosclerotic plaque burden were not assessed in this study, but it was reported previously that perindopril treatment inhibited the development of atherosclerotic lesions in diabetic ApoE-deficient mice (Candido et al., 2002), while anti-atherosclerotic effect of MNA was described in apolipoprotein E (ApoE)/low-density lipoprotein receptor (LDLR)-deficient mice (Mateuszuk et al., 2016). Given the pathophysiological role of endothelial dysfunction in atherogenesis, effects of MNA or perindopril on endothelial function could contribute to the anti-atherosclerotic action of these compounds.

Conclusion

Using functional 3D MRI-based assays of endothelial function and biochemical measurements of ACE/Ang II, ACE2/Ang-(1–7) balance and L-Arg/ADMA ratio in plasma, we demonstrated significant vasoprotective effects of MNA (100 mg/kg b.w./day), which were comparable with that afforded by perindopril (10 mg/kg b.w./day), a well-known ACE inhibitor. Although effects of MNA were less pronounced as compared with perindopril after 1-month treatment, after 2-month treatment, either treatment modality resulted in a comparable effect including reversal of Ach-induced vasoconstriction response to vasodilatation and a concomitant decrease in endothelial permeability. Furthermore, functional improvement of endothelial function by MNA or perindopril treatment was in both cases associated with the inhibition of ACE/Ang II axis, the parallel activation of ACE2/Ang-(1–7) axis, and an increase in L-Arg/ADMA ratio in plasma. Given that improvement in endothelial function by ACE-Is contributes to their therapeutic efficacy (Chłopicki and Gryglewski, 2005), presented in the current study findings of endothelial profile of MNA being similar to ACE-I (perindopril) in in vivo settings bring important novel perspectives to understand therapeutic efficacy of MNA (Gebicki et al., 2003; Wozniacka et al., 2005; Chlopicki et al., 2007; Bartuś et al., 2008; Bryniarski et al., 2008; Brzozowski et al., 2008; Watała et al., 2009; Sternak et al., 2010; Przyborowski et al., 2015; Blazejczyk et al., 2016; Jakubowski et al., 2016; Mateuszuk et al., 2016). Moreover, our approach for the in vivo assessment of endothelial phenotype based on a retrospectively self-gated 3D gradient-echo sequence, MRI-based technique, concomitant with the biochemical assays of two important systems of endothelial regulation, ACE/Ang-II-ACE2/Ang-(1–7) and L-Arg/ADMA, proves to be a useful tool for the in vivo endothelial profiling of compounds to demonstrate convincingly their beneficial effects on endothelial function.

Author Contributions

Conceived and designed the study: AB and SC. Performed the study: AB, MO, UT, EK, and KJ. Analyzed the data: AB and MO. Provided the analytical tools: RS, TS. Drafted the manuscript: AB, MO, and SC. All authors have corrected or have approved the final version of the manuscript.

Conflict of Interest Statement

SC is a coinventor of the patent on the use of quaternary pyridinium salts as vasoprotective agents. The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

This study was supported by the National Science Centre, grant Symfonia no. DEC-2015/16/W/NZ4/00070 and partially by the European Union from the resources of the European Regional Development Fund under the Innovative Economy Programme (grant coordinated by JCET-UJ, No POIG. 01.01.02-00-069/09). We would like to thank Renata Kostogrys for support and assistance.

Abbreviations

ACE
angiotensin-converting enzyme
ACE-I
angiotensin-converting enzyme inhibitor
Ach
acetylcholine
ACN
acetonitrile
ADMA
asymmetric dimethylarginine
Ang
angiotensin
ApoE/LDLR-/-
atherosclerotic mice
Arg
arginine
BCA
brachiocephalic artery
CA
contrast agent
COX-2
cyclooxygenase 2
CS
calibration standards
DDAH
dimethylarginine dimethylaminohydrolase
ECs
endothelial cells
eNOS
endothelial nitric oxide synthase
FA
formic acid
Hcy
homocysteine
HFD
high-fat diet
IL-4
interleukin-4
IS
internal standard
LC-MS/MS
liquid chromatography-tandem mass spectrometry
Met
L-methionine
MNA
1-methylnicotinamide
MRI
magnetic resonance imaging
MRM
multiple reaction monitoring mode
NA
nicotinamide
NFPA
nonafluoropentanoic acid
NNMT
nicotinamide N-methyltransferase
NO
nitric oxide
Npx50
number of pixels for which T1 had changed more than 50% after contrast agent administration
PGI2
prostacyclin
QC
quality control samples
RAS
renin-angiotensin system
ROI
region of interest
ROS
reactive oxygen species
RS
real samples
SDMA
symmetric dimethylarginine
VFA
Variable Flip Angle technique
VSMCs
vascular smooth muscle cells
T1
relaxation time
TNF-α
tumor necrosis factor-α

Supplementary Material

The Supplementary Material for this article can be found online at: http://journal.frontiersin.org/article/10.3389/fphar.2017.00183/full#supplementary-material

References

  • Aksoy S., Szumlanski C. L., Weinshilboum R. M. (1994). Human liver nicotinamide N-methyltransferase. cDNA cloning, expression, and biochemical characterization. J. Biol. Chem. 269 14835–14840. [PubMed]
  • Anderson T. J., Gerhard M. D., Meredith I. T., Charbonneau F., Delagrange D., Creager M. A., et al. (1995). Systemic nature of endothelial dysfunction in atherosclerosis. Am. J. Cardiol. 75 71B–74B. 10.1016/0002-9149(95)80017-M [PubMed] [Cross Ref]
  • Bar A., Skorka T., Jasinski K., Sternak M., Bartel Ż., Tyrankiewicz U., et al. (2016). Retrospectively-gated MRI for in vivo assessment of endothelium-dependent vasodilatation and endothelial permeability in murine models of endothelial dysfunction. NMR Biomed. 29 1088–1097. 10.1002/nbm.3567 [PubMed] [Cross Ref]
  • Bartuś M., Łomnicka M., Kostogrys R., Kaźmierczak P., Watała C., Słominska E. M., et al. (2008). 1-methylnicotinamide (MNA) prevents endothelial dysfunction in hypertriglyceridemic and diabetic rats. Pharm. Rep. 60 127–138. [PubMed]
  • Blazejczyk A., Switalska M., Chlopicki S., Marcinek A., Gebicki J., Nowak M., et al. (2016). 1-Methylnicotinamide and its structural analog 1,4-dimethylpyridine for the prevention of cancer metastasis. J. Exp. Clin. Cancer Res. 35:110 10.1186/s13046-016-0389-9 [PMC free article] [PubMed] [Cross Ref]
  • Böger R. H. (2003). The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc. Res. 59 824–833. 10.1016/S0008-6363(03)00500-5 [PubMed] [Cross Ref]
  • Böger R. H., Bode-Böger S. M., Sydow K., Heistad D. D., Lentz S. R. (2000). Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 20 1557–1564. 10.1161/01.ATV.20.6.1557 [PubMed] [Cross Ref]
  • Böger R. H., Bode-Böger S. M., Szuba A., Tsao P. S., Chan J. R., Tangphao O., et al. (1998). Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role hypercholesterolemia. Circulation 98 1842–1847. 10.1161/01.CIR.98.18.1842 [PubMed] [Cross Ref]
  • Böger R. H., Bode-Böger S. M., Thiele W., Junker W., Alexander K., Frölich J. C. (1997). Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 95 2068–2074.10.1161/01.CIR.95.8.2068 [PubMed] [Cross Ref]
  • Botnar R. M., Makowski M. R. (2012). Cardiovascular magnetic resonance imaging in small animals. Prog. Mol. Biol. Transl. Sci. 105 227–261.10.1016/B978-0-12-394596-9.00008-1 [PubMed] [Cross Ref]
  • Bryniarski K., Biedron R., Jakubowski A., Chlopicki S., Marcinkiewicz J. (2008). Anti-inflammatory effect of 1-methylnicotinamide in contact hypersensitivity to oxazolone in mice; involvement of prostacyclin. Eur. J. Pharmacol. 578 332–338. 10.1016/j.ejphar.2007.09.011 [PubMed] [Cross Ref]
  • Brzozowski T., Konturek P. S., Chlopicki S., Sliwowski Z., Pawlik M., Ptak-Belowska A., et al. (2008). Therapeutic potential of 1-methylnicotinamide against acute gastric lesions induced by stress: role of endogenous prostacyclin and sensory nerves. J. Pharmacol. Exp. Ther. 326 105–116. 10.1124/jpet.108.136457 [PubMed] [Cross Ref]
  • Cahill P. A., Redmond E. M. (2016). Vascular endothelium – gatekeeper of vessel health. Atherosclerosis 248 97–109. 10.1016/j.atherosclerosis.2016.03.007 [PubMed] [Cross Ref]
  • Candido R., Jandeleit-Dahm K. A., Cao Z., Nesteroff S. P., Burns W. C., Twigg S. M., et al. (2002). Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 106 246–253. 10.1161/01.CIR.0000021122.63813.32 [PubMed] [Cross Ref]
  • Canton G., Hippe D. S., Sun J., Underhill H. R., Kerwin W. S., Tang D., et al. (2012). Characterization of distensibility, plaque burden, and composition of the atherosclerotic carotid artery using magnetic resonance imaging. Med. Phys. 39 6247–6253. 10.1118/1.4754302 [PubMed] [Cross Ref]
  • Cavalcante J. L., Lima J. A., Redheuil A., Al-Mallah M. H. (2011). Aortic stiffness: current understanding and future directions. J. Am. Coll. Cardiol. 57 1511–1522. 10.1016/j.jacc.2010.12.017 [PubMed] [Cross Ref]
  • Cheng H. L., Wright G. A. (2006). Rapid high-rsolution T1 mapping by variable flip angles: accurate and precise measurements in the presence of radiofrequency field inhomogeneity. Magn. Reson. Med. 55 566–574.10.1002/mrm.20791 [PubMed] [Cross Ref]
  • Chłopicki S., Gryglewski R. J. (2005). Angiotensin converting enzyme (ACE) and Hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium. Pharm. Rep. 57(Suppl.) 86–96. [PubMed]
  • Chlopicki S., Swies J., Mogielnicki A., Buczko W., Bartus M., Lomnicka M., et al. (2007). 1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway. Br. J. Pharmacol. 152 230–239. 10.1038/sj.bjp.0707383 [PMC free article] [PubMed] [Cross Ref]
  • Closs E. I., Ostad M. A., Simon A., Warnholtz A., Jabs A., Habermeier A., et al. (2012). Impairment of the extrusion transporter for asymmetric dimethyl-L-arginine: a novel mechanism underlying vasospastic angina. Biochem. Biophys. Res. Commun. 423 218–223. 10.1016/j.bbrc.2012.05.044 [PubMed] [Cross Ref]
  • Crauwels H. M., Van Hove C. E., Holvoet P., Herman A. G., Bult H. (2003). Plaque-associated endothelial dysfunction in apolipoprotein E-deficient mice on a regular diet. effect of human apolipoprotein AI. Cardiovasc. Res. 59 189–199. 10.1016/S0008-6363(03)00353-5 [PubMed] [Cross Ref]
  • Csányi G., Gajda M., Franczyk-Zarow M., Kostogrys R., Gwoźdź P., Mateuszuk L., et al. (2012). Functional alterations in endothelial NO, PGI2 and EDHF pathways in aorta in ApoE/LDLR-/- mice. Prostaglandins Other Lipid Mediat. 98 107–115. 10.1016/j.prostaglandins.2012.02.002 [PubMed] [Cross Ref]
  • Dharmashankar K., Widlansky M. E. (2010). Vascular endothelial function and hypertension: insights and directions. Curr. Hypertens. Rep. 12 448–455. 10.1007/s11906-010-0150-2 [PMC free article] [PubMed] [Cross Ref]
  • Dong B., Zhang C., Feng J. B., Zhao Y. X., Li S. Y., Yang Y. P., et al. (2008). Overexpression of ACE2 enhances plaque stability in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 28 1270–1276. 10.1161/ATVBAHA.108.164715 [PubMed] [Cross Ref]
  • Franses J. W., Drosu N. C., Gibson W. J., Chitalia V. C., Edelman E. R. (2013). Dysfunctional endothelial cells directly stimulate cancer inflammation and metastasis. Int. J. Cancer 133 1334–1344. 10.1002/ijc.28146 [PMC free article] [PubMed] [Cross Ref]
  • Frolow M., Drozdz A., Kowalewska A., Nizankowski R., Chlopicki S. (2015). Comprehensive assessment of vascular health in patients; towards endothelium-guided therapy. Pharm. Rep. 67 786–792. 10.1016/j.pharep.2015.05.010 [PubMed] [Cross Ref]
  • Gebicki J., Sysa-Jedrzejowska A., Adamus J., Woźniacka A., Rybak M., Zielonka J. (2003). 1-methylnicotinamide: a potent anti-inflammatory agent of vitamin origin. Pol. J. Pharm. 55 109–112. [PubMed]
  • Gotschy A., Bauer E., Schrodt C., Lykowsky G., Ye Y. X., Rommel E., et al. (2013). Local arterial stiffening assessed by MRI precedes atherosclerotic plaque formation. Circulation 6 916–923. 10.1161/CIRCIMAGING.113.000611 [PubMed] [Cross Ref]
  • Gryglewski R. J., Chlopicki S., Swies J. (2005). In vivo endothelial interaction between ACE and COX inhibitors. Prostaglandins Leukot. Essent. Fatty Acids 72 129–131. 10.1016/j.plefa.2004.10.010 [PubMed] [Cross Ref]
  • Gryglewski R. J., Swies J., Uracz W., Chłopicki S., Marcinkiewicz E. (2003). Mechanisms of angiotensin-converting enzyme inhibitor induced thrombolysis in wistar rats. Thromb. Res. 110 323–329. 10.1016/j.thromres.2003.08.005 [PubMed] [Cross Ref]
  • Halcox J. P., Schenke W. H., Zalos G., Mincemoyer R., Prasad A., Waclawiw M. A., et al. (2002). Prognostic value of coronary vascular endothelial dysfunction. Circulation 106 653–658. 10.1161/01.CIR.0000025404.78001.D8 [PubMed] [Cross Ref]
  • Herold V., Wellen J., Ziener C. H., Weber T., Hiller K. H., Nordbeck P., et al. (2009). In vivo comparison of atherosclerotic plaque progression with vessel wall strain and blood flow velocity in apoE(-/-) mice with MR microscopy at 17.6 T. MAGMA 22 159–166. 10.1007/s10334-008-0160-0 [PubMed] [Cross Ref]
  • Huang A., Pinto J. T., Froogh G., Kandhi S., Qin J., Wolin M. S., et al. (2015). Role of homocysteinylation of ACE in endothelial dysfunction of arteries. Am. J. Physiol. Heart Circ. Physiol. 308 H92–H100. 10.1152/ajpheart.00577.2014 [PubMed] [Cross Ref]
  • Jakubowski A., Sternak M., Jablonski K., Ciszek-Lenda M., Marcinkiewicz J., Chlopicki S. (2016). 1-methylnicotinamide protects against liver injury induced by concanavalin A via a prostacyclin-dependent mechanism: a possible involvement of IL-4 and TNF-α. Int. Immunopharmacol. 31 98–104. 10.1016/j.intimp.2015.11.032 [PubMed] [Cross Ref]
  • Jiang F., Yang J., Zhang Y., Dong M., Wang S., Zhang Q., et al. (2014). Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets. Nat. Rev. Cardiol. 11 413–426. 10.1038/nrcardio.2014.59 [PubMed] [Cross Ref]
  • Jiang N., Wang M., Song J., Liu Y., Chen H., Mu D., et al. (2016). N-methylnicotinamide protects against endothelial dysfunction and attenuates atherogenesis in apolipoprotein E-deficient mice. Mol. Nutr. Food Res. 60 1625–1636. 10.1002/mnfr.201400013.This [PubMed] [Cross Ref]
  • Kao C. H., Chen J. K., Kuo J. S., Yang V. C. (1995). Visualization of the transport pathways of low density lipoproteins across the endothelial cells in the branched regions of rat arteries. Atherosclerosis 116 27–41. 10.1016/0021-9150(95)05519-3 [PubMed] [Cross Ref]
  • Karbach S., Wenzel P., Waisman A., Munzel T., Daiber A. (2014). eNOS uncoupling in cardiovascular diseases–the role of oxidative stress and inflammation. Curr. Pharm. Des. 20 3579–3594. 10.2174/13816128113196660748 [PubMed] [Cross Ref]
  • Kostogrys R. B., Franczyk-Żarów M., Maślak E., Gajda M., Mateuszuk L., Jackson C. L., et al. (2012). Low carbohydrate, high protein diet promotes atherosclerosis in apolipoprotein E/low-density lipoprotein receptor double knockout mice (apoE/LDLR(-/-)). Atherosclerosis 223 327–331. 10.1016/j.atherosclerosis.2012.05.024 [PubMed] [Cross Ref]
  • Lee J. M., Shirodaria C., Jackson C. E., Robson M. D., Antoniades C., Francis J. M., et al. (2007). Multi-modal magnetic resonance imaging quantifies atherosclerosis and vascular dysfunction in patients with type 2 diabetes mellitus. Diab. Vasc. Dis. Res. 4 44–48. 10.3132/dvdr.2007.005 [PMC free article] [PubMed] [Cross Ref]
  • Lobbes M. B., Miserus R. J., Heeneman S., Passos V. L., Mutsaers P. H., Debernardi N., et al. (2009). Atherosclerosis: contrast- enhanced mr imaging of vessel wall in rabbit model — comparison of gadofosveset and gadopentetate dimeglumine. Radiology 250 682–691. 10.1148/radiol.2503080875 [PubMed] [Cross Ref]
  • Lovren F., Pan Y., Quan A., Teoh H., Wang G., Shukla P. C., et al. (2008). Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. 295 H1377–H1384. 10.1152/ajpheart.00331.2008 [PubMed] [Cross Ref]
  • Ludmer P. L., Selwyn A. P., Shook T. L., Wayne R. R., Mudge G. H., Alexander R. W., et al. (1986). Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N. Engl. J. Med. 315 1046–1051. 10.1056/NEJM198610233151702 [PubMed] [Cross Ref]
  • Marti C. N., Gheorghiade M., Kalogeropoulos A. P., Georgiopoulou V. V., Quyyumi A. A., Butler J. (2012). Endothelial dysfunction, arterial stiffness, and heart failure. J. Am. Coll. Cardiol. 60 1455–1469. 10.1016/j.jacc.2011.11.082 [PubMed] [Cross Ref]
  • Mateuszuk L., Jasztal A., Maslak E., Gasior-Glogowska M., Baranska M., Sitek B., et al. (2016). Antiatherosclerotic effects of 1-methylnicotinamide in apolipoprotein E/low-density lipoprotein receptor-deficient mice: a comparison with nicotinic acid. J. Pharmacol. Exp. Ther. 356 514–524. 10.1124/jpet.115.228643 [PubMed] [Cross Ref]
  • Mittal M., Siddiqui M. R., Tran K., Reddy S. P., Malik A. B. (2014). Reactive oxygen species in inflammation and tissue injury. Antioxid. Redox Signal. 20 1126–1167. 10.1089/ars.2012.5149 [PMC free article] [PubMed] [Cross Ref]
  • Olkowicz M., Chlopicki S., Smolenski R. T. (2015). Perspectives for angiotensin profiling with liquid chromatography/mass spectrometry to evaluate ACE/ACE2 balance in endothelial dysfunction and vascular pathologies. Pharmacol. Rep. 67 778–785. 10.1016/j.pharep.2015.03.017 [PubMed] [Cross Ref]
  • Olkowicz M., Chlopicki S., Smolenski R. T. (2016). A primer to angiotensin peptide isolation, stability, and analysis by nano-liquid chromatography with mass detection, in Thatcher SE. Methods Mol. Biol. (in press).
  • Pedersen S. F., Thrysoe S. A., Paaske W. P., Thim T., Falk E., Ringgaard S., et al. (2011). CMR assessment of endothelial damage and angiogenesis in porcine coronary arteries using gadofosveset. J. Cardiovasc. Magn. Reson. 13:10 10.1186/1532-429X-13-10 [PMC free article] [PubMed] [Cross Ref]
  • Phinikaridou A., Andia M. E., Protti A., Indermuehle A., Shah A., Smith A., et al. (2012). Noninvasive magnetic resonance imaging evaluation of endothelial permeability in murine atherosclerosis using an albumin-binding contrast agent. Circulation 126 707–719. 10.1161/CIRCULATIONAHA.112.092098 [PubMed] [Cross Ref]
  • Przyborowski K., Wojewoda M., Sitek B., Zakrzewska A., Kij A., Wandzel K., et al. (2015). Effects of 1-methylnicotinamide (MNA) on exercise capacity and endothelial response in diabetic mice. PLoS ONE 10:e0130908 10.1371/journal.pone.0130908 [PMC free article] [PubMed] [Cross Ref]
  • Redheuil A. (2014). Cardiovascular aging: insights from local and regional measures of aortic stiffness using magnetic resonance imaging. Artery Res. 8 66–72. 10.1016/j.artres.2014.01.005 [Cross Ref]
  • Schächinger V., Britten M. B., Zeiher A. M. (2000). Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101 1899–1906. 10.1161/01.CIR.101.16.1899 [PubMed] [Cross Ref]
  • Schnabel R., Blankenberg S., Lubos E., Lackner K. J., Rupprecht H. J., Espinola-Klein C., et al. (2005). Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the atherogene study. Circ. Res. 97 e53–e59. 10.1161/01.RES.0000181286.44222.61 [PubMed] [Cross Ref]
  • Schulz E., Wenzel P., Münzel T., Daiber A. (2014). Mitochondrial redox signaling: interaction of mitochondrial reactive oxygen species with other sources of oxidative stress. Antioxid. Redox Signal. 20 308–324. 10.1089/ars.2012.4609 [PMC free article] [PubMed] [Cross Ref]
  • Smolenska Z., Smolenski R. T., Zdrojewski Z. (2016). Plasma concentrations of amino acid and nicotinamide metabolites in rheumatoid arthritis – potential biomarkers of disease activity and drug treatment. Biomarkers 21 218–224. 10.3109/1354750X.2015.1130746 [PubMed] [Cross Ref]
  • Sternak M., Khomich T. I., Jakubowski A., Szafarz M., Szczepañski W., Białas M, et al. (2010). Nicotinamide N-methyltransferase (NNMT) and 1-methylnicotinamide (MNA) in experimental hepatitis induced by concanavalin A in the mouse. Pharmacol. Rep. 62 483–493. 10.1016/S1734-1140(10)70304-2 [PubMed] [Cross Ref]
  • Steven S., Münzel T., Daiber A. (2015). Exploiting the pleiotropic antioxidant effects of established drugs in cardiovascular disease. Int. J. Mol. Sci. 16 18185–18223. 10.3390/ijms160818185 [PMC free article] [PubMed] [Cross Ref]
  • Suda O., Tsutsui M., Morishita T., Tasaki H., Ueno S., Nakata S., et al. (2004). Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Arterioscler. Thromb. Vasc. Biol. 24 1682–1688. 10.1161/01.ATV.0000136656.26019.6e [PubMed] [Cross Ref]
  • Surdacki A., Nowicki M., Sandmann J., Tsikas D., Boeger R. H., Bode-Boeger S. M., et al. (1999). Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J. Cardiovasc. Pharmacol. 33 652–658. 10.1097/00005344-199904000-00020 [PubMed] [Cross Ref]
  • Teixido-Tura G., Redheuil A., Rodríguez-Palomares J., Gutiérrez L., Sánchez V., Forteza A., et al. (2014). “Aortic biomechanics by magnetic resonance: early markers of aortic disease in marfan syndrome regardless of aortic dilatation?” Int. J. Cardiol. 171 56–61. 10.1016/j.ijcard.2013.11.044 [PubMed] [Cross Ref]
  • Thatcher S. E., Zhang X., Howatt D. A., Lu H., Gurley S. B., Daugherty A., et al. (2011). Angiotensin-converting enzyme 2 deficiency in whole body or bone marrow-derived cells increases atherosclerosis in low-density lipoprotein receptor-/- mice. Arterioscler. Thromb. Vasc. Biol. 31 758–765. 10.1161/ATVBAHA.110.221614 [PMC free article] [PubMed] [Cross Ref]
  • Thomas M. C., Pickering R. J., Tsorotes D., Koitka A., Sheehy K., Bernardi S., et al. (2010). Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ. Res. 107 888–897.10.1161/CIRCRESAHA.110.219279 [PubMed] [Cross Ref]
  • Villeneuve N., Fortuno A., Sauvage M., Fournier N., Breugnot C., Jacquemin C., et al. (2003). Persistence of the nitric oxide pathway in the aorta of hypercholesterolemic apolipoprotein-E-deficient mice. J. Vasc. Res. 40 87–96. 10.1159/000070705 [PubMed] [Cross Ref]
  • Walczak M., Suraj J., Kus K., Kij A., Zakrzewska A., Chlopicki S. (2015). Towards a comprehensive endothelial biomarkers profiling and endothelium-guided pharmacotherapy. Pharmacol. Rep. 67 771–777. 10.1016/j.pharep.2015.06.008 [PubMed] [Cross Ref]
  • Wang J., Qiu M., Kim H., Constable R. T. (2006). T1 measurements incorporating flip angle calibration and correction in vivo. J. Magn. Reson. 182 283–292. 10.1016/j.jmr.2006.07.005 [PubMed] [Cross Ref]
  • Wang Y., Tikellis C., Thomas M. C., Golledge J. (2013). Angiotensin converting enzyme 2 and atherosclerosis. Atherosclerosis 226 3–8. 10.1016/j.atherosclerosis.2012.08.018 [PubMed] [Cross Ref]
  • Watała C., Kaźmierczak P., Dobaczewski M., Przygodzki T., Bartuś M., Łomnicka M., et al. (2009). Anti-diabetic effects of 1-methylnicotinamide (MNA) in streptozocin-induced diabetes in rats. Pharmacol. Rep. 61 86–98. 10.1016/S1734-1140(09)70010-6 [PubMed] [Cross Ref]
  • Wozniacka A., Wieczorkowska M., Gebicki J., Sysa-Jedrzejowska A. (2005). Topical application of 1-methylnicotinamide in the treatment of rosacea: a pilot study. Clin. Exp. Dermatol. 30 632–635. 10.1111/j.1365-2230.2005.01908.x [PubMed] [Cross Ref]
  • Zhou R., Yazdi A. S., Menu P., Tschopp J. (2011). A role for mitochondria in NLRP3 inflammasome activation. Nature 469 221–225. 10.1038/nature09663 [PubMed] [Cross Ref]
  • Zhuo J. L., Mendelsohn F. A., Ohishi M. (2002). Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension 39 (2 Pt 2) 634–638. 10.1161/hy0202.103417 [PubMed] [Cross Ref]

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA